Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eli Lilly and : NIH Halts Study Exploring Treating Covid-19 With Lilly Antibody, Remdesivir

10/26/2020 | 07:27pm EST

By Peter Loftus

Federal health researchers have halted testing a combination of Eli Lilly & Co.'s Covid-19 antibody drug and remdesivir in hospitalized Covid-19 patients, after an independent committee found a lack of a benefit.

The National Institute of Allergy and Infectious Diseases, which is funding the study, said Monday it was planning to test other experimental drugs as Covid-19 treatments in the study. Lilly said it would continue testing its antibody drug in other studies.

The decision may not affect the U.S. Food and Drug Administration's appraisal of Lilly's antibody drug, which is up for authorization as a solitary treatment for patients with mild to moderate Covid-19 and not hospitalized.

Enrollment in the study of the drug combination had been paused earlier this month due to a potential safety concern.

An independent board overseeing the trial found a difference in the clinical status between Covid-19 patients who received the Lilly drug and those who got a placebo.

NIAID had said it ordered the pause out of an abundance of caution, and Lilly said it supported the move to ensure patient safety.

After reviewing updated data from the study, however, the independent board on Monday found no significant differences in safety outcomes between patients getting the Lilly drug and those on placebo.

Instead, the board's decision to recommend that no further patients be given the Lilly drug in the study "was driven by lack of clinical benefit" in hospitalized patients, NIAID said.

Some 326 patients had been enrolled in the study, and researchers will continue to follow them for 90 days.

Lilly's drug, code named LY-CoV555, is essentially a clone of immune-system agents known as antibodies that fight infections.

Lilly is codeveloping the drug with AbCellera Biologics Inc., of Vancouver, Canada, which isolated antibodies from a blood sample taken from one of the earliest Americans to recover from Covid-19.

The trial testing whether adding LY-CoV555 to Gilead Sciences Inc.'s remdesivir would benefit people hospitalized with Covid-19 began in August. Remdesivir is approved to treat serious hospitalized Covid-19 patients.

The trial's close is a setback in efforts to find better treatments for Covid-19, but Lilly said the drug continues to have potential to help people at earlier stages of Covd-19 than hospitalized patients.

Lilly said Monday all other studies of LY-CoV555 are still ongoing, including in nonhospitalized patients and residents and staff at long-term care facilities.

The Indianapolis-based company also said that while there was insufficient evidence that its drug improved clinical outcomes in hospitalized patients, it was confident that the drug may prevent progression of disease for those earlier in the course of Covid-19.

A separate study testing the drug alone found that it reduced hospitalizations in patients with mild to moderate forms of the disease.

Based on that study, Lilly asked the FDA earlier this month to authorize emergency use of the antibody in nonhospitalized people with recently diagnosed mild-to-moderate Covid-19.

Write to Peter Loftus at peter.loftus@wsj.com

(END) Dow Jones Newswires

10-26-20 2026ET

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -0.06% 145.56 Delayed Quote.10.82%
GILEAD SCIENCES, INC. 0.74% 61.12 Delayed Quote.-5.94%
All news about ELI LILLY AND COMPANY
11/25ELI LILLY AND COMPANY : - Lilly to Participate in Evercore ISI 3rd Annual Health..
AQ
11/24ELI LILLY AND : Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Confe..
PR
11/24ELI LILLY AND : to Supply Bamlanivimab to Treat Covid-19 in Canada
DJ
11/24UPS Preparing to Help Ship, Store Covid-19 Vaccines
DJ
11/23REGENERON PHARMACEUTICALS : U.S. to begin distributing Regeneron's COVID-19 anti..
RE
11/23ELI LILLY AND COMPANY : - Lilly and Precision BioSciences Announce Genome Editin..
AQ
11/23ELI LILLY AND COMPANY : - Lilly's neutralizing antibody bamlanivimab receives in..
AQ
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
DJ
11/21REGENERON PHARMACEUTICALS : FDA Authorizes Regeneron's Covid-19 Antibody Cocktai..
DJ
11/20ELI LILLY AND : Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives ..
AQ
More news
Financials (USD)
Sales 2020 23 681 M - -
Net income 2020 6 011 M - -
Net Debt 2020 11 184 M - -
P/E ratio 2020 22,9x
Yield 2020 2,03%
Capitalization 132 B 132 B -
EV / Sales 2020 6,05x
EV / Sales 2021 5,42x
Nbr of Employees 33 625
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 164,58 $
Last Close Price 145,65 $
Spread / Highest target 37,3%
Spread / Average Target 13,0%
Spread / Lowest Target -17,6%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY10.82%132 044
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389